Tonix Pharmaceuticals Holding, based in Chatham, New Jersey, specializes in developing therapeutics for CNS disorders and immunology, with a portfolio including TNX-102 SL for fibromyalgia and TNX-1500 for autoimmune diseases. Founded in 2010, the company employs 103 people and markets Zembrace SymTouch and Tosymra.
Tonix Pharmaceuticals Holding (TNXP) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Tonix Pharmaceuticals Holding's actual EPS was -$23.00, beating the estimate of -$299.20 per share, resulting in a 92.31% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
